Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Chen, Weena J Y ^a   Rijzewijk, Luuk J ^a   van der Meer, Rutger W ^b   Heymans, Martijn W ^a   van Duinkerken, Eelco ^a   Lubberink, Mark ^a   Lammertsma, Adriaan A ^a   Lamb, Hildo J ^b   de Roos, Albert ^b   Romijn, Johannes A ^b   Smit, Jan W A ^b   Bax, Jeroen J ^b   Bjerre, Mette ^c   Frystyk, Jan ^c   Flyvbjerg, Allan ^c   Diamant, Michaela ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adiponectin; Arterial function; Cardiac function; Myocardial metabolism; Osteoprotegerin; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; OSTEOPROTEGERIN; BIOLOGICAL MARKER;

ADULT; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; GLUCOSE METABOLISM; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; STRESS ECHOCARDIOGRAPHY; WAIST CIRCUMFERENCE; AORTA; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; HEART; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPONECTIN; AORTA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; GLUCOSE; HEART; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; OSTEOPROTEGERIN; POSITRON-EMISSION TOMOGRAPHY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79960556393     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-67     Document Type: Article

References (39)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234. 10.1056/NEJM199807233390404, 9673301.
2. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de RA, Twisk JW, Heine RJ, Lammertsma AA, Smit JW, Diamant M. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009, 54:1524-1532. 10.1016/j.jacc.2009.04.074, 19815124.
3. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de RA, Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003, 42:328-335. 10.1016/S0735-1097(03)00625-9, 12875772.
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319. 10.1016/S0092-8674(00)80209-3, 9108485.
5. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002, 22:549-553. 10.1161/01.ATV.0000012303.37971.DA, 11950689.
6. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 2010, 6:94-101. 10.1038/nrendo.2009.266, 20098449.
7. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007, 49:1392-1398. 10.1161/HYPERTENSIONAHA.107.087742, 17470718.
8. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005, 111:2461-2468. 10.1161/01.CIR.0000165119.62099.14, 15883214.
9. Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y. Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost 2010, 8:1170-1175. 10.1111/j.1538-7836.2010.03833.x, 20230427.
10. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006, 47:1850-1857. 10.1016/j.jacc.2005.12.054, 16682312.
11. Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, Rossing P. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010, 33:2561-2566. 10.2337/dc10-0858, 20929997.
12. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone?. Diabetes Care 2003, 26:2442-2450. 10.2337/diacare.26.8.2442, 12882876.
13. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935. 10.1210/jc.86.5.1930, 11344187.
14. Tuttolomondo A, La PS, Di RD, Bellia C, Caruso A, Lo SB, Guercio G, Diana G, Ciaccio M, Licata G, Pinto A. Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol 2010, 9:50. 10.1186/1475-2840-9-50, 2946274, 20836881.
15. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005, 54:534-539.
16. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de RA, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52:1793-1799. 10.1016/j.jacc.2008.07.062, 19022158.
17. van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de RA, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009, 119:2069-2077. 10.1161/CIRCULATIONAHA.108.803916, 19349323.
18. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985, 8:491-498. 10.2337/diacare.8.5.491, 4053936.
19. van der Meer RW, Diamant M, Westenberg JJ, Doornbos J, Bax JJ, de RA, Lamb HJ. Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus. J Cardiovasc Magn Reson 2007, 9:645-651.
20. Resnick LM, Militianu D, Cunnings AJ, Pipe JG, Evelhoch JL, Soulen RL. Direct magnetic resonance determination of aortic distensibility in essential hypertension: relation to age, abdominal visceral fat, and in situ intracellular free magnesium. Hypertension 1997, 30:654-659.
21. Paelinck BP, de RA, Bax JJ, Bosmans JM, van Der Geest RJ, Dhondt D, Parizel PM, Vrints CJ, Lamb HJ. Feasibility of tissue magnetic resonance imaging: a pilot study in comparison with tissue Doppler imaging and invasive measurement. J Am Coll Cardiol 2005, 45:1109-1116. 10.1016/j.jacc.2004.12.051, 15808772.
22. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
23. Knaapen P, Boellaard R, Gotte MJ, Dijkmans PA, van Campen LM, de Cock CC, Luurtsema G, Visser CA, Lammertsma AA, Visser FC. Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy. J Nucl Med 2004, 45:1299-1304.
24. Hermansen F, Rosen SD, Fath-Ordoubadi F, Kooner JS, Clark JC, Camici PG, Lammertsma AA. Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols. Eur J Nucl Med 1998, 25:751-759. 10.1007/s002590050279, 9662598.
25. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985, 5:584-590. 10.1038/jcbfm.1985.87, 4055928.
26. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006, 154:75-81. 10.1530/eje.1.02049, 16381994.
27. Andersen KK, Frystyk J, Wolthers OD, Heuck C, Flyvbjerg A. Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab 2007, 92:1857-1862. 10.1210/jc.2006-2310, 17284625.
28. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005, 28:2176-2180. 10.2337/diacare.28.9.2176, 16123486.
29. Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne JF, Cristol JP, Dupuy AM. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007, 30:2934-2939. 10.2337/dc07-0992, 17712025.
30. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, Hansen JB. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost 2011, 9:638-644. 10.1111/j.1538-7836.2011.04222.x, 21284802.
31. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268. 10.1101/gad.12.9.1260, 316769, 9573043.
32. Vik A, Mathiesen EB, Noto AT, Sveinbjornsson B, Brox J, Hansen JB. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 2007, 191:128-134. 10.1016/j.atherosclerosis.2006.03.002, 16620835.
33. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, Hansen JB. Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromso Study. J Thromb Haemost 2010, 8:2133-2139. 10.1111/j.1538-7836.2010.03990.x, 20738762.
34. Kozakova M, Muscelli E, Flyvbjerg A, Frystyk J, Morizzo C, Palombo C, Ferrannini E. Adiponectin and left ventricular structure and function in healthy adults. J Clin Endocrinol Metab 2008, 93:2811-2818. 10.1210/jc.2007-2580, 18397982.
35. Gustafsson S, Lind L, Zethelius B, Venge P, Flyvbjerg A, Soderberg S, Ingelsson E. Adiponectin and cardiac geometry and function in elderly: results from two community-based cohort studies. Eur J Endocrinol 2010, 162:543-550. 10.1530/EJE-09-1006, 20008076.
36. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762. 10.1161/CIRCULATIONAHA.104.530972, 16157772.
37. Cavusoglu E, Chopra V, Battala V, Ruwende C, Yanamadala S, Eng C, Pinsky DJ, Marmur JD. Baseline plasma adiponectin levels as a predictor of left ventricular systolic dysfunction in patients referred for coronary angiography. Am J Cardiol 2008, 101:1073-1078. 10.1016/j.amjcard.2007.12.008, 18394435.
38. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, McMurray JJ. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007, 28:829-835. 10.1093/eurheartj/ehm033, 17403719.
39. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006, 55:1954-1960. 10.2337/db05-1525, 16804063.